Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques

Citations of this article
Mendeley users who have this article in their library.


Various inflammatory stimuli that activate the nuclear factor kappa B (NF-κB) signaling pathway converge on a serine/threonine kinase that displays a key role in the activation of NF-κB: the I kappa B kinase β (IKK-β). Therefore, IKK-β is considered an interesting target for combating inflammation and cancer. In our study, we developed a ligand-based pharmacophore model for IKK-β inhibitors. This model was employed to virtually screen commercial databases, giving a focused hit list of candidates. Subsequently, we scored by molecular shape to rank and further prioritized virtual hits by three-dimensional shape-based alignment. One out of ten acquired and biologically tested compounds showed inhibitory activity in the low micromolar range on IKK-β enzymatic activity in vitro and on NF-κB transactivation in intact cells. Compound 8 (2-(1-adamantyl)ethyl 4-[(2,5-dihydroxyphenyl)methylamino]benzoate) represents a novel chemical class of IKK-β inhibitors and shows that the presented model is a valid approach for identification and development of new IKK-β ligands. © 2010 Elsevier Ltd. All rights reserved.




Noha, S. M., Atanasov, A. G., Schuster, D., Markt, P., Fakhrudin, N., Heiss, E. H., … Wolber, G. (2011). Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques. Bioorganic and Medicinal Chemistry Letters, 21(1), 577–583.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free